Codagenix Phase. Codagenix Announces Safety and Immunogenicity Data from Phase
Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies Explore Codagenix, Inc. Together with preclinical toxicology data and demonstrated clinical safety of this attenuated influenza virus after intranasal administration in healthy individuals, CodaLytic emerges as a Results demonstrate CoviLiv, a novel intranasal live-attenuated COVID-19 vaccine candidate, induces robust humoral and cellular immunity in A Phase 1 clinical trial in healthy adults reached its primary endpoint, demonstrating both safety and an anti-RSV cellular immune response. Results demonstrate CoviLiv, a novel intranasal live-attenuated COVID-19 vaccine candidate, induces robust humoral and cellular immunity in healthy adults. , October 24, 2023 – Codagenix Inc. ^ "Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Codagenix Inc. Codagenix is a clinical-stage biotechnology Back to news Clinical Trials Arena 2022 / News Coverage Codagenix and SII begin subject dosing in Phase III Covid-19 vaccine trial Codagenix is combining codon deoptimization with live-attenuated viruses for a vaccine and therapeutic platform poised to transform global health. 88 million will support activities to advance CodaVax-DENV into the clinic Farmingdale, N. , July 22, 2025 /PRNewswire/ — STV is a placebo-controlled, Phase 3 safety and efficacy study with the primary endpoint of prevention of confirmed COVID-19 clinical disease. In addition, Codagenix recently announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration Codagenix has concluded the dosing of subjects in its Phase I clinical trial of a universal, live-attenuated influenza vaccine, CodaVax-H1N1. Its intranasal COVID‑19 vaccine "CoviLiv" is in international Phase 3 trials. FARMINGDALE, N. , June 14, 2022 /PRNewswire/ -- Codagenix Inc. Use the PitchBook Platform to explore the full profile. Completes Dosing for Phase 1 Trial of Live-Attenuated, Intranasal Vaccine for Respiratory Syncytial Virus (RSV) This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety of and immune response to CodaVax-RSV in Codagenix will develop nOPV-maxSD vaccine candidates with its proprietary synthetic biology to further improve genetic stability FARMINGDALE, N. , a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, today announced that it Codagenix sees expanding horizons in vaccine development Codagenix, partnering with the Serum Institute of India, began dosing an . , a clinical-stage synthetic biology Codagenix is moving its rational virus design platform forward with a new Phase I trial of its live attenuated respiratory syncytial virus ^ "COVI-VAC for SARS-CoV-2 (COVID-19)". CoviLiv is a novel intranasal live-attenuated COVID-19 vaccine candidate, derived from SARS-CoV-2/Wuhan that was synthetically engineered utilizing Codagenix’ codon pair Information on valuation, funding, cap tables, investors, and executives for Codagenix. with its drug pipeline, therapeutic area, technology platform, 8 clinical trials, 55 news, and 25 literature, Disease Domain:Infectious Award valued at $5. CoviLiv is being investigated in The global Phase 3 trial will evaluate the safety, efficacy, and immunogenicity of CoviLiv against circulating SARS-CoV-2 strains as compared to placebo in up to 20,000 healthy adults in This study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety of and immune response to CodaVax-RSV in For this initial phase, Codagenix will synthetically modify the genomes of nOPV strains to produce new nOPV-maxSD strains with intent to establish in vitro proof of concept Against the backdrop of a global push for new COVID vaccines that can provide broader and longer lasting protection, Codagenix today Codagenix has advanced multiple live attenuated vaccine candidates into clinical trials. About Codagenix, Inc. A Based on the results of this study, a Phase 2 dose confirming study will explore efficacy during the RSV season in 2023-2024. Y. With completion of the STV study, Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study. Codagenix, Inc. Retrieved 8 June 2021. , a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology Codagenix Inc.